23 Spam-Free Article(s) Found
https://www.zacks.com/stock/news/2241446/bristol-myers-bmy-gets-fda-nod-for-breyanzi-s-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241446
Mar 15, 2024 - Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
zc:-3282508303580057856
0
https://www.zacks.com/stock/news/2244465/bristol-myers-squibb-bmy-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2244465
Mar 21, 2024 - In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.59, marking a -0.56% move from the previous day.
zc:3552244431912288268
0
https://www.zacks.com/stock/news/2244198/biotech-stock-roundup-gern-crnx-gain-on-updates-bmy-s-car-t-cell-therapy-news-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2244198
Mar 21, 2024 - Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.
zc:-3980058176579956040
0